CMIB is currently working on the development of better patient selection and risk stratification in these areas:

• Better characterise the faulty valves, and how they impact the heart.
• Prediction of recurrence of atrial fibrillation after ablation.
• Better characterise the phenotype of hypertrophic cardiomyopathy, and predict its adverse clinical outcomes.
• Better understanding of the aetiology and stage of heart failure with preserved ejection fraction. Prediction of positive responders to cardiac resynchronization therapy.
• Better stratification of subjects with aortic stenosis.
• Better characterisation of the impact of a premature birth or a restricted growth in the placenta.